Spero Therapeutics, Inc.
SPRO· Nasdaq
Released Aug 6, 2020, after the close
10-Q filed Aug 6, 2020, 37 days after period end · 0001564590-20-037710
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $51.00K | $67.00K | $463.00K | $249.00K |
| Net Income | -$17.50M | -$13.20M | -$9.96M | -$9.17M |
| EPS Diluted |
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR
| -$0.85 |
| -$0.74 |
| -$0.69 |
| -$36.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.